DexCom (DXCM) Price Target Increased to $148.00 by Analysts at Jefferies Financial Group

DexCom (NASDAQ:DXCM) had its target price hoisted by Jefferies Financial Group to $148.00 in a research note released on Wednesday, The Fly reports. The firm currently has a buy rating on the medical device company’s stock. Jefferies Financial Group also issued estimates for DexCom’s Q3 2019 earnings at $0.00 EPS and Q4 2019 earnings at $0.21 EPS.

A number of other equities analysts have also issued reports on the company. Northland Securities raised DexCom from an under perform rating to a market perform rating in a research report on Wednesday, September 12th. Stephens upped their target price on DexCom from $135.00 to $160.00 and gave the company an overweight rating in a research report on Thursday, August 23rd. Canaccord Genuity upped their target price on DexCom from $125.00 to $150.00 and gave the company a buy rating in a research report on Thursday, August 23rd. Piper Jaffray Companies upped their target price on DexCom to $150.00 and gave the company an overweight rating in a research report on Thursday, August 2nd. Finally, BidaskClub raised DexCom from a buy rating to a strong-buy rating in a research report on Tuesday, August 21st. Eight equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $132.50.

NASDAQ DXCM traded up $3.51 on Wednesday, reaching $148.16. The company had a trading volume of 78,522 shares, compared to its average volume of 1,186,998. The stock has a market cap of $11.74 billion, a PE ratio of -255.37 and a beta of 0.60. DexCom has a 1 year low of $48.90 and a 1 year high of $148.56. The company has a quick ratio of 4.62, a current ratio of 4.89 and a debt-to-equity ratio of 0.69.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.29. DexCom had a negative return on equity of 3.08% and a net margin of 4.72%. The firm had revenue of $266.70 million during the quarter, compared to analysts’ expectations of $242.72 million. The business’s quarterly revenue was up 44.5% on a year-over-year basis. Sell-side analysts anticipate that DexCom will post -0.49 EPS for the current fiscal year.

In related news, EVP Steven Robert Pacelli sold 3,114 shares of the company’s stock in a transaction that occurred on Thursday, August 23rd. The stock was sold at an average price of $139.96, for a total transaction of $435,835.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Andrew K. Balo sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $124.25, for a total value of $621,250.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 170,392 shares of company stock worth $23,416,280. Corporate insiders own 1.80% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. State Board of Administration of Florida Retirement System increased its position in DexCom by 0.4% in the second quarter. State Board of Administration of Florida Retirement System now owns 120,747 shares of the medical device company’s stock worth $11,469,000 after buying an additional 470 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in DexCom by 9.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,552 shares of the medical device company’s stock worth $527,000 after buying an additional 471 shares during the period. Metropolitan Life Insurance Co. NY increased its position in DexCom by 7.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 6,879 shares of the medical device company’s stock worth $653,000 after buying an additional 486 shares during the period. Xact Kapitalforvaltning AB increased its position in DexCom by 4.1% in the second quarter. Xact Kapitalforvaltning AB now owns 12,700 shares of the medical device company’s stock worth $1,206,000 after buying an additional 500 shares during the period. Finally, Oppenheimer & Co. Inc. increased its position in DexCom by 23.8% in the third quarter. Oppenheimer & Co. Inc. now owns 3,282 shares of the medical device company’s stock worth $469,000 after buying an additional 630 shares during the period.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: Why do corrections happen?

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply